Iron chelation efficiency of deferasirox (Exjade®, ICL670) in patients with transfusional hemosiderosis

被引：0
|
作者：
Porter, J
Borgna-Pignatti, C
Baccarani, M
Saviano, A
Abish, S
Malizia, R
Nick, H
Opitz, H
Rabault, B
Gathmann, I
Marks, P
机构：
[1] Univ Coll Hosp, London, England
[2] Univ Ferrara, I-44100 Ferrara, Italy
[3] Policlin S Orsola, Bologna, Italy
[4] Azienda Ospe Rilievo Nazl A Cararelli, Naples, Italy
[5] Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada
[6] Azienda Ospe Villa Sofia, Palermo, Italy
[7] Novartis, Basel, Switzerland
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2690
引用
收藏
页码：755A / 756A
页数：2
相关论文
共 50 条
  • [31] Long-term efficacy and safety with deferasirox (Exjade®, ICL670), a once-daily oral iron chelator, in pediatric patients
    Piga, Antonio
    Vichinsky, Elliott
    Forni, Gian Luca
    Kilinc, Yurdanur
    Maseruka, Henry
    Kattamis, Antonios
    BLOOD, 2007, 110 (11) : 815A - 815A
  • [32] Deferasirox (Exjadeg®, ICL670) is effective and tolerable in β-thalassemia patients with high iron burden and history of inadequate chelation therapy.
    Taher, A.
    El-Beshlawy, A.
    Al Jefri, A.
    Elalfy, M.
    Al Zir, K.
    Daar, S.
    Darnanhouri, G.
    Krahn, U.
    Hadler, D.
    BLOOD, 2006, 108 (11) : 32B - 32B
  • [33] The once-daily oral chelator deferasirox (exjade®, ICL670) reduces iron overload in a murine model of juvenile hemochromatosis
    Nick, Hanspeter
    Allegrini, Peter
    Fozard, Lucy
    Junker, Ursula
    Rojkjaer, Lisa
    O'Reilly, Terrence
    AMERICAN JOURNAL OF HEMATOLOGY, 2007, 82 (06) : 555 - 555
  • [34] Deferasirox (Exjade®, ICL670) treatment of inadequately chelated β-thalassemia patients from the Middle East:: The ESCALATOR trial.
    Taher, A
    El-Beshlawy, A
    Al Jefri, A
    El Alfy, M
    Al Zir, K
    Daar, S
    Al-Damanhouri, G
    Hadler, D
    Krahn, U
    BLOOD, 2005, 106 (11) : 40B - 41B
  • [35] Long-term experience with deferasirox (ICL670), a once-daily oral iron chelator, in the treatment of transfusional iron overload
    Cappellini, M. D.
    Taher, A.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (13) : 2391 - 2402
  • [36] IRON CHELATION THERAPY WITH DEFERASIROX (ICL670) REDUCES SERUM FERRITIN (SF) AND LABILE PLASMA IRON (LPI) IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS)
    List, A. F.
    Baer, M. R.
    Steensma, D.
    Raza, A.
    Esposito, J.
    Virkus, J.
    Feigert, J.
    Besa, E.
    Paley, C.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2008, 93 : 91 - 92
  • [37] Dose-dependent reductions in serum ferritin correlate with changes in serum transaminase levels during long-term iron chelation therapy with deferasirox (Exjade®, ICL670)
    Brissot, P.
    Cianciulli, P.
    Cario, H.
    Rabault, B.
    Deugnier, Y.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S77 - S77
  • [38] Comparison of LIC obtained from biopsy, BLS and R2-MRI in iron overloaded patients with β-thalassemia, treated with deferasirox (Exjade®, ICL670)
    Piga, A
    Fischer, R
    Harmatz, P
    St Pierre, TG
    Longo, F
    Fung, E
    Engelhardt, R
    Perrotta, S
    Galanello, R
    Capra, M
    Vichinsky, E
    Janka-Schaub, G
    Masera, G
    Cianciulli, P
    Coates, T
    Janssen, G
    Jeng, M
    Lai, ME
    Salles, G
    Cole, P
    Alberti, D
    Rosenkranz, G
    Opitz, H
    BLOOD, 2005, 106 (11) : 755A - 755A
  • [39] LONG-TERM IRON CHELATION THERAPY WITH DEFERASIROX IN PEDIATRIC PATIENTS WITH TRANSFUSIONAL HEMOSIDEROSIS (ENTRUST)
    Vichinsky, Elliott
    El-Beshlawy, Amal
    Alzoebie, Azzam
    Kamdem, Annie
    Koussa, Suzanne
    Chotsampancharoen, Thirachit
    Bruederle, Andreas
    Han, Jackie
    Elalfy, Mohsen
    AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (08) : E444 - E444
  • [40] Liver iron concentration measurements using MRI R2 in MDS patients in a deferasirox (Exjade®, ICL670) phase II study.
    Greenberg, Peter L.
    Schiffer, Charles A.
    Koller, Charles Asa
    Kang, Barinder
    Decker, Jodie
    Paley, Carole
    BLOOD, 2006, 108 (11) : 297B - 297B
12345